Altimmune ALT Proceeds From Sale And Maturity Of Available For Sale Securities
Proceeds From Sale And Maturity Of Available For Sale Securities at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's proceeds from sale and maturity of available for sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's proceeds from sale and maturity of available for sale securities?
- Altimmune (ALT) reported proceeds from sale and maturity of available for sale securities of $39.62M in Q1 2026.
- How has Altimmune's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Altimmune's proceeds from sale and maturity of available for sale securities increased by 4.2% year-over-year, from $38.04M to $39.62M.
- What is the long-term trend for Altimmune's proceeds from sale and maturity of available for sale securities?
- Over 3 years (2021 to 2025), Altimmune's proceeds from sale and maturity of available for sale securities has grown at a 12.5% compound annual growth rate (CAGR), from $107.43M to $152.99M.